Belite Bio Inc ADR

Yahoo Finance • last month

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that h... Full story

Yahoo Finance • last month

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that h... Full story

Yahoo Finance • last month

Stock Market Today: Nasdaq, S&P 500 Mount Midday Recovery As Market Returns From Holiday

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Dec. 1, 2025. You can... Full story

Yahoo Finance • last month

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstr... Full story

Yahoo Finance • 2 months ago

Belite Bio outlines regulatory path and $275.6M cash position while preparing for Tinlarebant commercialization

Earnings Call Insights: Belite Bio (BLTE) Q3 2025 MANAGEMENT VIEW * CEO Yu-Hsin Lin highlighted the completion of Phase III PHOENIX trial enrollment with 530 subjects for geographic atrophy and the completion of the Phase III DRAGON tr... Full story

Yahoo Finance • 2 months ago

Belite Bio GAAP EPS of -$0.28 beats by $0.20

* Belite Bio press release [https://seekingalpha.com/pr/20300408-belite-bio-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update] (BLTE [https://seekingalpha.com/symbol/BLTE]): Q3 GAAP EPS of -$0.28 beats by $0.20... Full story

Yahoo Finance • 2 months ago

After-Hours Earnings Report for November 10, 2025 : OXY, RKLB, ASTS, RGTI, SARO, WULF, BLTE, PLUG, MLYS, TDW, BBAI, JAMF

The following companies are expected to report earnings after hours on 11/10/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Occidental Petroleum Corporation (OXY)is reporting for the quarter ending Sep... Full story

Yahoo Finance • 2 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held Novem... Full story

Yahoo Finance • 2 months ago

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused... Full story

Yahoo Finance • 3 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international... Full story

Yahoo Finance • 3 months ago

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have s... Full story

Yahoo Finance • 3 months ago

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have s... Full story

Yahoo Finance • 3 months ago

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focuse... Full story

Yahoo Finance • 4 months ago

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast sub... Full story

Yahoo Finance • 4 months ago

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to... Full story

Yahoo Finance • 5 months ago

Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance

Belite Bio (NASDAQ:BLTE) reported increased expenses and widening losses in its Q2 2025 financial results presentation on August 11, while highlighting progress in its late-stage clinical trials for retinal diseases. The ophthalmology-focu... Full story

Yahoo Finance • 5 months ago

Belite Bio GAAP EPS of -$0.31 beats by $0.10

* Belite Bio press release [https://seekingalpha.com/pr/20195622-belite-bio-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update] (NASDAQ:BLTE [https://seekingalpha.com/symbol/BLTE]): Q2 GAAP EPS of -$0.31 beats... Full story

Yahoo Finance • 5 months ago

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period)Enrollment completed wit... Full story

Yahoo Finance • 5 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing... Full story

Yahoo Finance • 6 months ago

Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress

Investing.com - H.C. Wainwright has reiterated a Buy rating and $100.00 price target on Belite Bio, Inc, ADR (NASDAQ:BLTE), currently trading at $56.81 with a market cap of $1.85 billion, following the completion of enrollment in a key cli... Full story